[ad_1]
Arcatron Mobility, a fast-growing consumer healthcare company, has raised growth funding from OrbiMed, a global investment firm focused on healthcare. Existing investors BL Taparia Family Office, Chona Family Office, MGA Ventures, and the founders of Arcatron also participated in this funding round.
The funds will be used to strengthen research and development activities, develop new products, and strengthen branding and marketing.
Pune-based Arcatron, under its flagship brand ‘Frido’, manufactures wheelchairs for patients with limited mobility, orthopedic insoles for pain relief and increased comfort, and ergonomic We offer mobility aids such as cushions. The company offers its products on all major e-commerce platforms, its own website, and through its over 1,000 stores nationwide.
Arcatron founders Ganesh Sonawane and Arif Khan use this investment to expand product development and reach more customers, apart from the potential opportunities opened up by the partnership with OrbiMed. I see it as a catalyst for
“We are very impressed with the team’s expertise in product development and marketing and are excited to partner with Alcatron in building a leading consumer healthcare company,” said Partner and Senior, OrbiMed Asia. said Dr. Sunny Sharma, managing director and co-owner with Mr. Sumona. Mr. Chakraborty of OrbiMed will join his Arcatron board of directors.
OrbiMed (OrbiMed Advisors) is an investment firm based in New York City, USA. Focuses on public and private investments in the healthcare and biotechnology industries.
With $21 billion in total assets under management (AUM), OrbiMed is considered one of the world’s largest specialized healthcare investment firms. For comparison, the PE firm recently raised about $4.3 billion to invest in healthcare startups across the continent.
The fund’s Indian portfolio includes Asian Institute of Medical Sciences (AIMS), Marksands Pharma, LifeCell, Capiva, Bharat Serum, tertiary hospital chain KIMS and clinical research organization Ekron Akunova, among others.
Most of OrbiMed’s deals are in the $15 million to $35 million range.
[ad_2]
Source link
